Results 221 to 230 of about 99,201 (311)

Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting. [PDF]

Blood Cancer J
Lu X, Song Z, Wang C, Pan B, Xu Z, Wang Z, Wang H, Wang X, Tang B.   +8 more
europepmc   +1 more source

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

Advanced Science, EarlyView.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang, Congxue Hu, Hang Zhao, Xiao Peng, Yiming Yan, Jiasi Wang, Wenqi Jiang, Depeng Mu, Yan Cao, Xia Li, Yunpeng Zhang   +10 more
wiley   +1 more source

Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

Annals of Gastroenterological Surgery, EarlyView.
In this multicenter retrospective study conducted by the Biliary Tract Club, we compared survival outcomes between gemcitabine–cisplatin–S‐1 (GCS) and gemcitabine–cisplatin (GC) in patients with unresectable biliary tract cancer, with a particular focus on conversion surgery. GCS was associated with longer overall and progression‐free survival compared
Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, Toru Ishikawa, Takanori Morikawa, Jun Hanaoka, Haruki Mori, Hidenori Toyoda, Tsuyoshi Sanuki, Misaki Yokoi, Hiroyuki Shibata, Koji Fukuda, Kazuhito Kawata, Koji Amaya, Takashi Ito, Masaaki Hidaka, Atsushi Naganuma, Keishi Sugimachi, Satoshi Toshiyama, Makoto Yamasaki, Masaki Kaibori   +27 more
wiley   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta-Analyses. [PDF]

Cancer Med
Yu Z, Wang Z, Xie L, Xu J, Min L, Li L, Niu T.   +6 more
europepmc   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management. [PDF]

Hum Vaccin Immunother
Pan Y, Yang H, Shao J, Qiang X, Wang Q.
europepmc   +1 more source

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

American Journal of Hematology, EarlyView.
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros‐Miralles, Cécile Arnaud, Isabelle Genty, Marie Petras, Catherine Paillard, Gonzalo De Luna, Benoit Meunier, Isabelle Thuret, Annie Kamdem, Corinne Pondarré, Giovanna Cannas, Christelle Chantalat‐Auger, Nadia Firah, Sophie Pertuisel, Laure Joseph, Florence Missud, Mariane de Montalembert, Corinne Guitton, Claire Pluchart, Valentine Brousse, Monique Elmaleh, Vincent Gajdos, Emmanuella Leveillé, Ekaterina Belozertseva, Mabel Gaba, Catherine Poirot, Virginie Barraud‐Lange, Philippe Chadebech, France Pirenne, Myriam Bernaudin, Bénédicte Neven, Pierre Frange, Marie Angoso, Karima Yakouben, Bénédicte Bruno, Nathalie Dhédin, Jean‐Hugues Dalle, Regis Peffault Delatour, Camille Jung   +40 more
wiley   +1 more source

Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation. [PDF]

Bioimpacts
B Allela OQ, Shareef A, Kyada A, Malathi H, Maharana L, Puri D, Gupta H, Polatova D, Sameer HN, Yaseen A, H Athab Z, Adil M.   +11 more
europepmc   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source